TB Therapeutic Drug Monitoring: is it resistance, non-adherence, or malabsorption?
For healthcare organizations and professionals (B2B) · Physician-led · Updated 2026-07-12 · CLIA #45D2048957 · CAP #8722734
Serum levels for ten anti-TB drugs, by LC-MS/MSCLIA #45D2048957 · CAP #8722734 · Same-day results · Walk-ins welcome
Auspicious Laboratory measures serum concentrations of ten anti-tuberculosis drugs by LC-MS/MS — isoniazid, rifampin, rifabutin, pyrazinamide, ethambutol, cycloserine, ethionamide, moxifloxacin, linezolid and pretomanid — in-house, in a CLIA-certified (#45D2048957) and CAP-accredited (#8722734) Houston laboratory. Therapeutic drug monitoring answers the question a culture cannot: when a patient on directly observed therapy is not converting, is the drug not being taken, not being absorbed, or not working? Low exposure with good adherence is a dosing problem, not a resistance problem — and the two are managed in opposite directions. We report the concentration; the treating physician interprets it.
A patient who takes every dose and still cultures positive at month three is not automatically a treatment failure — and is not automatically resistant. Until you have the serum level, you cannot tell which.
What is therapeutic drug monitoring in tuberculosis, and why would a clinic order it?
TB regimens are dosed on weight and assumed absorption. That assumption fails often enough to matter: malabsorption, HIV co-infection, diabetes, gastrectomy or short-gut states, vomiting, drug–drug interactions (rifampin is a powerful enzyme inducer), and simple pharmacokinetic variability can all leave a fully adherent patient with peak concentrations well below the target range. The clinical picture is indistinguishable from non-adherence or acquired resistance — and each of those three has a completely different response.
Therapeutic drug monitoring (TDM) resolves the ambiguity with a number. A low peak with adequate adherence points to absorption or dosing, and the answer is a dose adjustment, not a new regimen. A normal peak in a slow responder points elsewhere — extent of disease, cavitation, or true resistance — and spares the patient a needless dose escalation.
Which drugs can Auspicious Laboratory measure?
Serum concentrations by LC-MS/MS, run in-house in our CLIA-certified, CAP-accredited Houston laboratory:
| Drug | Class / role | Why the level matters |
|---|---|---|
| Isoniazid | First-line | Acetylator status (NAT2) makes exposure vary several-fold between patients on the identical dose. |
| Rifampin | First-line, sterilizing | Low peaks are common and are associated with slow culture conversion; rifampin also induces the metabolism of many co-medications. |
| Pyrazinamide | First-line | Contributes most of the sterilizing effect in the first two months; low exposure is linked to poor outcome. |
| Ethambutol | First-line | Renally cleared — accumulation raises the risk of optic neuritis; underexposure weakens the companion drug. |
| Rifabutin | Rifamycin alternative | Used when rifampin interactions are unacceptable (HIV/ART); its own levels are interaction-sensitive. |
| Moxifloxacin | Fluoroquinolone | Rifampin lowers moxifloxacin exposure. Central to shorter and drug-resistant regimens. |
| Linezolid | Group A, MDR/XDR | The drug where TDM matters most: efficacy at trough, and myelosuppression and neuropathy driven by prolonged high exposure. A level can save the drug and the nerve. |
| Cycloserine | Group B, MDR | Narrow window — neuropsychiatric toxicity above it, failure below it. |
| Ethionamide | Group C, MDR | GI intolerance drives dose reduction; the level tells you whether the reduced dose is still therapeutic. |
| Pretomanid | BPaL / BPaLM regimens | New-generation regimen component — exposure data are still accumulating in routine practice. |
Specimen: serum. Method: LC-MS/MS. Reported to the ordering clinician; call the lab for current turnaround and for timed-draw instructions.
Who is TDM for? Six patients where the level changes the plan
- The slow responder — still smear- or culture-positive at 2 months on a fully supervised regimen (DOT).
- Malabsorption — HIV enteropathy, diabetic gastroparesis, chronic diarrhoea, gastrectomy, bariatric surgery, short bowel.
- Diabetes — associated with lower rifampin exposure and slower conversion.
- Drug–drug interaction — ART, azoles, anticoagulants, methadone, and anything else colliding with rifampin's induction.
- MDR/XDR regimens — especially anyone on linezolid, cycloserine or ethionamide, where the therapeutic window is narrow in both directions.
- Toxicity that looks dose-related — cytopenias or neuropathy on linezolid, optic symptoms on ethambutol, psychiatric symptoms on cycloserine.
How a clinic orders it
| Step | What happens |
|---|---|
| 1. Account | Contact the lab to open a provider account and receive requisitions and specimen-collection instructions. |
| 2. Timed draw | TDM is a timed test — a peak is typically drawn a set interval after the observed dose, with a second point if absorption is the question. The exact draw times must follow the ordering clinician's protocol; call us before the first patient so the timing and handling are right the first time. |
| 3. Handling | Serum, separated and frozen per instructions. Handling errors, not assay error, are the usual reason a TDM result cannot be interpreted. |
| 4. Report | Concentrations are reported to the ordering clinician, who interprets them against published target ranges in the context of the patient. |
What this service is and is not. We measure concentrations. We do not diagnose treatment failure, do not recommend a regimen, and do not adjust doses — those are clinical decisions made by the treating physician, and TDM targets should be applied per current CDC/ATS/IDSA guidance and the patient's full picture. We also do not perform TB diagnostic testing (culture, NAAT, IGRA) — this is drug-level measurement only.
Compliance note (AKS / Stark). Auspicious Laboratory does not pay for referrals, does not waive or discount patient responsibility to induce referrals, and does not provide items of value to ordering clinicians. Testing is performed only on a physician order, for a documented clinical purpose, and results are reported to the ordering clinician. Medical necessity and test selection are the clinician's decision.
FAQ
- Which anti-TB drugs can you measure?
- Ten, by LC-MS/MS in serum: isoniazid, rifampin, rifabutin, pyrazinamide, ethambutol, cycloserine, ethionamide, moxifloxacin, linezolid and pretomanid.
- Why would a level be low in a patient who is taking every dose?
- Because dose does not equal exposure. Malabsorption, HIV enteropathy, diabetic gastroparesis, gastrectomy, vomiting, enzyme induction by rifampin, and ordinary pharmacokinetic variability can all produce a sub-therapeutic peak in a fully adherent patient. That patient looks like a treatment failure and is not one.
- Does a normal level mean the patient is adherent?
- A therapeutic level at the expected time after an observed dose is evidence that the drug was absorbed on that occasion. TDM is not an adherence test and should not be used as one - it is a pharmacokinetic measurement, interpreted by the treating clinician.
- Do you also diagnose TB?
- No. This service measures drug concentrations only. TB diagnosis - culture, NAAT, IGRA, drug-susceptibility testing - is not on our menu.
- How is the sample collected and when?
- Serum, drawn at a defined interval after an observed dose - a peak, sometimes with a second point when absorption is in question. Timing is what makes the result interpretable, so call the lab before your first patient and we will send the collection and handling instructions.
- Is linezolid monitoring really worth it?
- It is the drug where clinicians most often say the level changed what they did. Efficacy tracks with trough exposure while myelosuppression and peripheral neuropathy track with prolonged high exposure, so the level is what lets you keep an effective drug in the regimen instead of stopping it after a cytopenia.
References
- CDC — Tuberculosis: clinical care and treatment.
- CDC / ATS / IDSA — Treatment of Drug-Susceptible Tuberculosis (MMWR Recommendations and Reports).
- ATS / CDC / IDSA — Treatment of Drug-Resistant Tuberculosis (linezolid, cycloserine, ethionamide toxicity and monitoring).
- WHO — Consolidated guidelines on drug-resistant tuberculosis treatment (BPaL/BPaLM).
- CMS — CLIA program; CAP accreditation.
Reach us — privately
No name needed to ask a question. Text is the fastest way to reach us.
Or send your details below — we will reply by text or email during open hours.